Patients with primary unresected locoregionally advanced HNSCC , in good clinical condition with unfavourable risk of recurrence , and no evidence of disease after chemoradiotherapy will be randomized @:@ to oral once-daily afatinib ( @ mg starting dose ) or placebo .